You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

197 Results
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Funding:
Exceptional Access Program
    zanubrutinib - For the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who have received at least one prior therapy; and for the treatment of adult patients with previously untreated CLL.
Mar 2024
Guidelines and Advice
Status: Current
ID: GL 19-7
Mar 2024
Drug
Other Name(s): Brukinsa®
Mar 2024
This is FR page
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Intent: Curative
Jul 2024
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Palliative
Oct 2024
Guidelines and Advice
Status: Current
ID: ES 6-25
Oct 2024
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Document

Pages